NASDAQ · VTRS
Healthcare · Drug Manufacturers - Specialty & Generic
$16.65
Up+$0.37 (+2.19%)
Updated Sep 16, 2026, 5:35 PM
SID Score
7.5/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
VTRS closed at $16.65 after 20 trading sessions, up 2.97% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $16.63 | $16.67 | $16.38 | $16.65 | 6.84M |
| Sep 14, 2026 | $16.64 | $16.8466 | $16.47 | $16.66 | 7.03M |
| Sep 11, 2026 | $16.50 | $16.65 | $16.32 | $16.51 | 12.17M |
| Sep 10, 2026 | $16.50 | $16.51 | $16.15 | $16.38 | 9.01M |
| Sep 9, 2026 | $16.72 | $16.84 | $16.40 | $16.50 | 6.51M |
| Sep 8, 2026 | $16.63 | $16.765 | $16.4201 | $16.61 | 4.39M |
| Sep 4, 2026 | $16.81 | $17.02 | $16.67 | $16.88 | 5.73M |
| Sep 3, 2026 | $17.222 | $17.28 | $16.81 | $16.94 | 8.03M |
| Sep 2, 2026 | $16.75 | $17.13 | $16.75 | $17.09 | 7.83M |
| Sep 1, 2026 | $16.62 | $16.91 | $16.51 | $16.63 | 6.53M |
| Aug 31, 2026 | $16.29 | $16.58 | $16.12 | $16.51 | 12.67M |
| Aug 28, 2026 | $16.93 | $17.01 | $16.295 | $16.34 | 6.22M |
| Aug 27, 2026 | $16.75 | $17.10 | $16.65 | $16.89 | 6.46M |
| Aug 26, 2026 | $16.72 | $17.065 | $16.65 | $16.85 | 7.4M |
| Aug 25, 2026 | $16.585 | $16.74 | $16.44 | $16.72 | 8.33M |
| Aug 24, 2026 | $16.25 | $16.58 | $16.19 | $16.54 | 4.98M |
| Aug 21, 2026 | $16.01 | $16.37 | $15.98 | $16.32 | 6.49M |
| Aug 20, 2026 | $16.068 | $16.26 | $16.04 | $16.12 | 5.33M |
| Aug 19, 2026 | $16.42 | $16.58 | $16.23 | $16.245 | 5.68M |
| Aug 18, 2026 | $16.36 | $16.52 | $16.165 | $16.17 | 9.05M |
The latest Smart Investors Daily articles mentioning VTRS.
VTRS research
Company profile and research snapshot.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 9, 2026 | Leerink Partners | Outperform | — |
| Sep 8, 2026 | Argus Research | Buy | — |
| May 19, 2026 | Barclays | Overweight | — |
| May 8, 2026 | Truist Securities | Buy | — |
| May 8, 2026 | JP Morgan | Neutral | — |
No generated briefing is available yet.
SeekingAlpha · Sep 9, 2026
Viatris' Q2 showed better earnings quality, with adjusted net income and EPS up 11% while free cash flow doubled year-over-year. Click here to read more.
Benzinga · Sep 9, 2026
Leerink Partners analyst Daniel Clark initiates coverage on Viatris (NASDAQ:VTRS) with a Outperform rating and announces Price Target of $20.
Benzinga · Sep 8, 2026
Argus Research analyst Jasper Hellweg maintains Viatris (NASDAQ:VTRS) with a Buy and raises the price target from $15 to $20.
Yahoo · Aug 31, 2026
Amphastar Pharmaceuticals, Sandoz and Viatris are positioned to benefit from new launches, biosimilars and a shift toward higher-value generics.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VTRS.
